E-news: No increase in miscarriage or malformation rates after cabergoline use

In their retrospective study, Lebbe and colleagues sought to investigate whether foetal exposure to the drug in women taking cabergoline at conception has adverse effects on the foetus.

They found that the occurrence of spontaneous miscarriage and pregnancies resulting in babies with congenital malformations was not influenced by the dose of cabergoline at conception, the time of drug withdrawal nor the cumulative foetal exposure to the drug.